Richard Miller

Company: Corvus Pharmaceuticals
Job title: Chief Executive Officer
Seminars:
Mupadolimab: A B Cell Activating Anti-CD73 Antibody for Immunotherapy of Cancer & Viral Diseases 2:15 pm
• Highlighting that Mupadolimab is a humanized anti CD73 antibody that activates B cells leading to expression of CD69, trafficking to lymph nodes and differentiation into antigen specific plasma cells and memory B cells • Demonstrating how the antibody has shown preliminary evidence of anti-tumor activity both as monotherapy and in combination with anti-PD1 in…Read more
day: Day Two